Contents

Contributors ........................................... ix
Welcome ................................................................ xi

Session I. CURRENT ACTIVITIES AND FUTURE GOALS OF ORPHAN
DISEASE AGENCIES
Introduction
Melvin H. Van Woert ...................................... 3
Orphan Drug Act
Melvin H. Van Woert ...................................... 7
Orphan Products Development and Some Methods for Maximizing the
Usefulness of Research on Rare Diseases
Marion J. Finkel ........................................... 11
The Orphan Products Board of the Department of Health & Human Services
Glenna M. Crooks ......................................... 19
The National Institutes of Health Small Business Innovation Research (SBIR)
Program: Opportunities for Orphan Drug Development
Lily O. Engstrom ........................................... 25
Discussion 1 .................................................. 31
The Pharmaceutical Manufacturers Association Commission on Drugs for
Rare Diseases
George S. Goldstein ....................................... 35
Generic Pharmaceutical Industry Association Orphan Drug Institute
William Haddad .......................................... 41
National Orphan Drugs and Devices Foundation
Joel Bennett ............................................... 47
The Consumer’s Role in Development of Orphan Drugs
Abbey S. Meyers ......................................... 51
Discussion 2 .................................................. 63

Session II. EXAMPLES OF CURRENT ORPHAN DRUG DEVELOPMENT
PROGRAMS
The National Cancer Institute’s Drug Development Program
Saul A. Schepartz .......................................... 73
## Contents

The Antiepileptic Drug Development Program: An Example of Government-Industry Collaboration  
B.G. White ........................................ 83

The Development of Orphan Drugs—A Pharmaceutical Company Perspective  
Jacob C. Stucki ........................................ 95

The Design and Development of Therapeutic Agents for Neuromuscular Diseases  
Neil J. Lewis ........................................ 105

Discussion 3 ........................................ 111

### Session III. ACADEMIC CENTER APPROACHES TO ORPHAN DRUG RESEARCH AND DEVELOPMENT

Academic Center Approaches to Orphan Drug Research and Development  
Fred P. Hauck, Eunyong Chung and Melvin H. Van Woert .......................... 115

The Fuel to Run the Orphan Drug Engine: A Medical School-based Orphan Disease Center Program  
George J. Brewer ........................................ 123

List of Voluntary Disease Organizations Which Participated in the Poster Session ........................................ 139

### Session IV. EXAMPLES OF INDIVIDUAL ORPHAN DRUG RESEARCH

Zinc as a Treatment for Wilson's Disease—An Orphan Among Orphans  
George J. Brewer and G.M. Hill ........................................ 143

Therapy of Cystinosis  
Jess G. Thoene ........................................ 157

Interstitial Cystitis  
Vicki Ratner ........................................ 163

### Session V. CHAIRMEN'S REPORT ON THREE WORKSHOPS

Workshop I Problems Associated With Developing Orphan Drugs Into Available Therapy  
Melvin H. Van Woert ........................................ 171

Workshop II Approaches to Cooperation on the Discovery of New Therapies for Rare Disorders  
Fred P. Hauck ........................................ 175

Workshop III The Role of Voluntary Disease Organizations in Research and Development of Orphan Drugs  
Ruby Horansky ........................................ 179

Discussion 4 ........................................ 183

Registrants ........................................ 185

Index ........................................ 197